Search

A newly identified group of immunosuppressive cells could provide insight into the effects of immunotherapy drugs.

… Tuesday, June 12, 2018 Summary MSK researchers have identified a new group of immunosuppressive cells that are affected in opposite ways by two common checkpoint inhibitors often given in combination. These cells are easily detectable in the blood and could help doctors make immunotherapy work better

MSK physicians and researchers discussed the latest trends in breast cancer research at the annual meeting held in San Antonio.

… Thursday, December 9, 2021 This week at the annual San Antonio Breast Cancer Symposium (SABCS), MSK researchers discussed some of the latest advances in breast cancer treatment and led educational sessions about improving ways to treat and manage the disease. Here are some of the noteworthy presentations

On Tuesday, December 2, MSK hosted "Demo Day 2025," a strong follow-up to the institution’s November 2025 “Innovation with Lasting Impact Summit” on entrepreneurship and innovation.

… Monday, January 12, 2026 On Tuesday, December 2, MSK hosted “ Demo Day 2025 ,” a strong follow-up to the institution’s November 2025 “ Innovation with Lasting Impact Summit ” on entrepreneurship and innovation. Fifteen cutting-edge companies selected to work with MSK’s laboratory, clinical, and digital

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.

… Saturday, June 2, 2018 Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the

… Wednesday, August 15, 2018 Summary A woman with an aggressive pituitary tumor responded well to immunotherapy. This successful treatment may lead to a clinical trial testing this approach in more people. Tumors of the pea-size pituitary gland, which sits at the base of the brain and secretes hormones

Part natural killer, part T cell, this hybrid immune cell has a “double sword” for fighting cancer.

… Tuesday, October 5, 2021 Pick up any immunology textbook and you’ll find an explanation of the “innate” and “adaptive” arms of the immune system. The innate arm is active from birth and responds to a predefined set of common threats; the adaptive arm takes time to develop but is more versatile at combatting

The new Fiona and Stanley Druckenmiller Center for Lung Cancer Research brings together MSK physicians and scientists in an intensive, multidisciplinary effort against the number-one cause of death from cancer in the nation.

… Friday, January 8, 2016 Summary Lung cancer causes more deaths in the United States than colon, breast, and prostate cancers combined. The Druckenmiller Center gathers scientists and physicians from across MSK to advance our understanding of the disease, examine novel treatments in preclinical models

Surgical resection of symptomatic, benign intradural extramedullary (IDEM) spine tumors provides rapid, significant, and durable improvements in patient-reported outcomes.

… Tuesday, March 2, 2021 Surgical resection of symptomatic, benign intradural extramedullary (IDEM) spine tumors provides rapid, significant, and durable improvements in patient-reported outcomes (PROs), according to our study published recently in Neurosurgery .   (1) Historically, these tumors have been

Chris Bourne is the first recipient of the MERIT Sawyers Fellowship.

… Thursday, February 10, 2022 Chris Bourne remembers the moment he knew he wanted to become a researcher. He had just completed freshman year at Swarthmore College in Pennsylvania and landed a summer internship with a pharmaceutical company near where he had grown up in South Brunswick, New Jersey. “I’

Breast conservation therapy as an initial treatment did not compromise survival outcomes compared to mastectomy in breast cancer patients under the age of 35.

… Thursday, January 14, 2021 Survival outcomes in breast cancer patients under the age of 35 was not compromised in those who had initial conservation therapy versus those who had mastectomy, according to our retrospective study published recently in the International Journal of Radiation Oncology .  (